Project HERCULES is led by Duchenne UK, with Fleur Chandler chairing the Steering Group and Josie Godfrey as Project Director. 

The core team includes:

Emily Crossley is joint CEO of Duchenne UK and leads on the project from within Duchenne UK. Previously a journalist, she set up Duchenne UK after her son Eli was diagnosed with Duchenne Muscular Dystrophy. She has brought her patient knowledge, along with the involvement of other patients to ensure that Project HERCULES meets expectations in delivering evidence and tools that actually reflect the experience of patients and families.  

Fleur Chandler chairs the Project HERCULES Steering Group. Fleur is a Health Economist with over 25 years’ experience in the pharmaceutical industry leading teams in health economics and health outcomes, and has a strong track record in Health Technology Assessment.  She is also the mother of a teenager with DMD and sits on the Patient Advisory Board of Duchenne UK.  She brought her personal and professional experience together to create the vision and concept for Project HERCULES and to guide the evidence generation activity to ensure that potential treatments for DMD are not denied on the basis of an inadequate HTA evidence base. 

Josie Godfrey is Strategic Director of Project HERCULES and brings over 10 years of experience in policy, public affairs and market access for rare diseases.  She provides strategic and stakeholder engagement support and is responsible for project delivery. Josie was previously the Associate Director at NICE, responsible for the Highly Specialised Technologies programme and is now the Director of JG Zebra Consulting. 

Project management support is provided through JG Zebra Consulting.

Industry Partners: 

We are very grateful to our 10 industry sponsors.

Other Partners: 

We are also delighted to have 3 universities, 3 HTA agencies, many global patient organisations,  key opinion leading clinicians and other experts coming together to support Project HERCULES and ensure we deliver the best possible evidence and tools to support HTA for DMD.

About Duchenne UK:

Duchenne UK has one clear aim – to end Duchenne, a devastating muscle-wasting disease. As the leading Duchenne charity in the UK, we connect the best researchers with industry, the NHS and families to challenge every stage of drug development to make the incurable, curable.

Together, we will find treatments and cures for this generation of patients with Duchenne.